Valence 로고
인기
로그인
Loading data for ERAS — first visit, this takes a few seconds.

관심목록에 추가

Erasca Inc.

NasdaqGS: ERAS · 실시간 가격 · USD
17.08
-0.99 (-5.48%)
종가 기준: Aug 21, 2026, 10:13 AM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

Erasca Inc.(ERAS) 주가, 분석 및 데이터

-5.48%
매수호가12.61
시가총액5.97B
매출 (ttm)n/a
순이익 (ttm)-287.22M
0.65
-0.9
n/a
-28.6
P/B (ttm)14.75
P/S (ttm)n/a
실적 발표일Nov 11, 2026
매도호가21.84
거래량2,666,428
평균 거래량 (20일)4,867,650
시가17.59
전일 종가18.07
일중 범위16.92 - 17.70
52주 범위1.33 - 24.28
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

ERAS 소개

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 ...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Jul 16, 2021
직원 수 103
상장 거래소 NasdaqGS
티커 ERAS
웹사이트 https://www.erasca.com
전체 기업 정보

재무 실적

2025년 Erasca의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -124.55M로, -22.95% 감소했습니다.

재무제표

어닝 서프라이즈

Erasca가 Aug 11, 2026에 분기 실적을 발표했습니다:
  • 매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -0.14 예상치 하회 -0.03, 및 -16.67% 전년 대비 감소.

    • 다음 실적 발표

    Erasca Inc.의 실적 발표 예정일은 Nov 11, 2026, 정규장 중입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1개월 전 · Simply Wall St.

    Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

    Erasca stock has delivered an extremely large 1 year gain, yet its valuation checks lean expensive, so the current price is testing how much optimism investors are willing to embed into the story this...

    news image

    1개월 전 · Simply Wall St.

    Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?

    Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a ...

    news image

    1개월 전 · Simply Wall St.

    Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers

    Erasca recently reported updated preliminary Phase 1 data for its oral pan-RAS molecular glue ERAS-0015, showing encouraging responses and a generally well-tolerated safety profile in RAS-mutant solid...

    news image

    1개월 전 · Insider Monkey

    Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results

    Erasca rallied by 8.94 percent on Tuesday to close at $19.50 apiece, as investor sentiment was boosted by the strong clinical trial results of its treatment candidate for RAS-mutant solid tumors, stre...

    news image

    1개월 전 · Barrons.com

    Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ List

    Robinhood Markets is added as a top stock for July. Micron and Oracle are among Mizuho Securities’ top picks for the month.

    2 페이지 중 1